32
DAFTAR PUSTAKA
1. The National Institute of Diabetes and Digestive and Kidney Disease. Prostate Enlargement: Benign Prostatic Hyperplasia [Internet]. 2014. Available from: https://www.niddk.nih.gov/health-information/health-topics/urologic-disease/benign-prostatic-hyperplasia-bph/Pages/facts.aspx 2. American Urological Association. American Urological Association
Guideline: Management of Benign Prostatic Hyperplasia (BPH) [Internet]. American Urological Association Education and Research, Inc.; 2010. Available from: https://www.auanet.org/common/pdf/education/clinical-guidance/Benign-Prostatic-Hyperplasia.pdf
3. Spatafora S, Casarico A, Fandella A, Galetti C, Hurle R, Mazzini E, et al. Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it.- PubMed – NCBI. Ncbi.nlm.nih.gov. 2012.
4. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19(Suppl 1):10-7.
5. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3.
6. Edwards J. Diagnosis and Management of Benign Prostatic Hyperplasia – American Family Physician. Aafp.org. 2008.
7. Deters LA. Benign Prostatic Hypertrophy: Practice Essentials, Background, Anatomy [Internet]. Emedicine.medscape.com. 2015 [cited 30 April 2016]. Available from: http://www.emedicine.medscape.com/article/437359-overview
8. Ikatan Ahli Urologi Indonesia. Clinical Pathway 10 Penyakit Urologi Tersering [Internet]. Ikatan Ahli Urologi Indonesia;2015. Available from: http://www.iaui.or.id/ast/file/CLINICAL_PATHWAY_(CP%20IAUI).pdf 9. Mochtar C, Umbas R, Soebadi D, Rasyid N, Nugroho B, Purnomo B et al.
Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/BPH) [Internet]. Jakarta: Ikatan Ahli Urologi Indonesia; 2015. Available from: http://www.iaui.or.id/ast/file/Guideline_BPH_(2015).pdf 10. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic
hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170. 11. Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and
hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med. 2015;8(7):11289-11294.
12. Tseng C. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer. 2013;13(1):1.
13. Breyer BN, Sarma AV. Hyperglycemia and Insulin Resistance and the Risk of BPH/LUTS: an Update of Recent Literature. Curr Urol Rep. 2014;15(12).
33
14. Ross AE, Rodriguez R. Development, Molecular Biology, and Physiology of the Prostate. In: Wein A, Kavoussi L, Partin A, Peters C, ed. by. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier, Inc.; 2016. p. 2393-2396.
15. Muruve NA. Prostate Anatomy: Overview, Gross Anatomy, Microscopic Anatomy [Internet]. Emedicine.medscape.com. 2013 [cited 3 May 2016]. Available from: http://www.emedicine.medscape.com/article/1923122-overview
16. Paulsen F, Weschke J. Sistem Urinarium Eferen. In: Pendit BU, Sugiharto L. by. Sobotta : Atlas Anatomi Manusia Jilid 2. 23rd ed. Jakarta: EGC, Inc.; 2012. p. 177.
17. Bushman W. Male Genital System and Lower Urinary Tract. In: Kumar V, Abbas A, Aster J, ed. by. Robbins' Basic Pathology. 9th ed. Philadelphia: Elsevier, Inc.; 2013. p. 663.
18. Presti J, Kane C, Shinohara K, Carroll P. Neoplasms of the Prostate Gland. In: Tanagho EMcAninch J, ed. by. Smith's General Urology. 17th ed. New York: The McGraw-Hill Companies, Inc.; 2008. p. 348-350.
19. Giri A, Edwards TL, Motley SS, Byerly SH, Fowke JH. Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. PLOS ONE. 2015;10(7):e0132028.
20. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20:S11-S18.
21. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(5 Suppl 1):1-6.
22. Trumble BC, Stieglitz J, Rodriguez DE, Linares EC, Kaplan HS, Gurven MD. Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forage-Horticulturalist. J Gerontol A Biol Sci Med Sci. 2015;70(10):1262-8.
23. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia. Rev Urol. 2004;6(Suppl 9):S3.
24. Nandeesha H. Benign prostatic hyperplasia: Dietary and metabolic risk factors. Int Urol Nephro. 2008;40(3):649-56.
25. Parsons J. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5(4):212-218.
26. Yelsel K, Alma E, Eken A, Gulum M, Ercil H, Ayyildiz A. Effect of obesity on International Prostate Symptom Score and prostate volume. Urol Ann. 2015.
27. Ylitalo AW, Santucci RA, Roberts KE. Digital Rectal Examination [Internet]. Emedicine.medscape.com. 2015 [cited 16 May 2016]. Available from: http://www.emedicine.medscape.com/article/1948001-overview 28. Gale EAM, Anderson JV. Diabetes mellitus and other disorders of
metabolism. In: Kumar P, Clark M. Clinical Medicine. 7th ed. Philadelphia: Elsevier, Inc.; 2009. p. 1029.
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010;33(Suppl 1):S62-S69.
34
30. Inzucchi S, Bergenstel R, Buse J, Diamant M, Ferrannini E, et al. Management in Type 2 Diabetes: A Patient-Centerd Approach: Position Statement of the American Diabetes Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379
31. Patel P, Macerollo A. Diabetes Mellitus: Diagnosis and Screening – American Family Physician. Aafp.org. 2010.
32. Farsani SF, Van Der Aa MP, Van Der Vorst MM, Knibbe CA, De Boer A. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approach- PubMed - NCBI. Ncbi.nlm.nih.gov. 2013.
33. Khardori R. Type 2 Diabetes Mellitus: Practice Essentials, Background, Pathophysiology [Internet]. Emedicine.medscape.com. 2015 [cited 25 May 2016]. Available from: http://emedicine.medscape.com/article/117853-overview
34. Kaku K. Pathophysiology of Type 2 Diabetes and Its Treatment Policy. JMAJ. 2010;53(1):41-46.
35. Olafsdottir E, Aspelund T, Sirgudsson G, Thorsson B, Benediktsson R, Harris T et al. Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in population-based study of older persons: from the Age, Gene/Environment Susceptibility–Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24(6):307-314
36. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Penyajian Pokok-Pokok Hasil Riset Kesehatan Dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013. 37. PERKENI. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe
2 di Indonesia. Jakarta: Perkumpulan Endokrinologi Indonesia; 2011.
38. Sarma A, Burke J, Jacobson D, McGree M, St. Sauver J, Girman C et al. Associations Between Diabetes and Clinical Markers of Benign Prostatic Hyperplasia Among Community-Dwelling Black and White Men. Diabetes Care. 2007;31(3):476-482.
39. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions. Int J Endocrinol. 2014:1-14.
40. Ghazali M, Sastromihardjo S, Soedjarwo S, Soelaryo T, Pramulyo H. Saudi cross-sectional. In: Sastroasmoro S, Ismael S, ed. by. Dasar-dasar Metodologi Penelitian Klinis. 4th ed. Jakarta: Sagung Seto; 2013. p. 130-144.
41. Dahlan M. Besar Sampel Aksis Deskriptif. In: Dahlan M, ed. by. Besar Sampel dalan Penelitian Kedokteran dan Kesehatan. 4th ed. Jakarta: Epidemiologi Indonesia; 2016. p. 11-68.
42. Yuri P, Wangge G, Abshari F, Satjakoesoemah Al, Perdana NR, Wijaya CD, et al. Indonesian prostate cancer risk calculator (IPCRC): an application for predicting prostate cancer risk (a multicenter study).- Pubmed – NCBI. Ncbi.mlm.nih.gov. 2015.
35
43. Amalia R. Faktor-Faktor Risiko terjadinya Pembesaran Prostat Jinak (Studi Kasus di RS Dr. Kariadi, RSI Sultan Agung, RS Roemani Semarang). Jurnal Epidemiologi. 2008.
44. Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome?. Urol. 2009;73(3):544-8.
45. Burke JP, Jacobson DJ, McGree ME, Roberts RO, Girman CJ, Lieber MM, Jacobsen SJ. Diabetes and benign prostatic hyperplasia progression in Olmsted County, Minnesota. Urol. 2006;67(1):22-5.
46. Yin Z, Yang JR, Rao JM, Song W, Zhou KQ. Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Andro. 2015;17(5):826.
47. Van Den Eeden SK, Ferrara A, Shan J, Jacobsen SJ, Quinn VP, Haque R, Quesenberry CP. Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study. BMC Urol. 2013;13(1):1.
48. Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, Hu Y, Zhang Y, Liao M, Mo Z. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urol. 2012;79(1):194-201.
